louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05821101: Clinical Outcomes of Clareon Vivity Intraocular Lens With Mini-Monovision Approach
Official title: Clinical Outcomes of Clareon Vivity Intraocular Lens With Mini-Monovision Approach
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Aphakia, Postcataract
Lead sponsor: Palo Alto Medical Foundation
Sponsor class: OTHER
Collaborators: name: Alcon Research
First posted: 2023-04-20
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Purpose is to study the clinical outcomes of Clareon Vivity and Clareon Vivity Toric intraocular lens (IOL) implants in patients who are planning to have cataract surgery in both eyes with a mini-monovision approach.

Detailed description: A "mini-monovision" approach is one in which the dominant eye is corrected for distance vision while the non-dominant eye is corrected with a small amount of nearsightedness (-0.5 diopters). This approach can have the benefit of increasing ability to see over a broad range of vision without glasses. The Clareon Vivity and Vivity Toric lenses have been approved by the U.S. Food and Drug Administration (FDA) for visual correction of aphakia in adult patients following cataract surgery. It has lens technology that provides an extended depth of focus (more range of clear vision for distance, intermediate and near vision) compared to a standard monofocal (single focus) lens. None of the procedures in this study are experimental. However, the study is seeking additional information on clinical outcomes of the mini-monovision approach specifically using the Clareon Vivity and Vivity Toric lenses.

Eligibility criteria: Inclusion Criteria:

* Adult patients with bilateral age-related visually significant cataracts in otherwise healthy eyes, undergoing bilateral sequential implantation within 21 days using Clareon Vivity and Clareon Vivity Torics
* IOL powers between +10D to +30.0D, T3-T6
* Potential acuity measured post-operatively 20/25 or better in both eyes

Exclusion Criteria:

* History of ocular or refractive surgery
* Ocular or systemic comorbidities that may alter or reduce visual acuity, contrast sensitivity, binocularity, or impair reading performance such as severe dry eye/ocular surface disease, glaucoma, macular degeneration, retinopathy, neuro-ophthalmic diseases, strabismus/amblyopia etc.
* Patients with irregular astigmatism, corneal dystrophies, pupil abnormalities, zonular laxity
* Intraoperative or postoperative complications

Primary outcomes:
measure: Binocular distance is target-corrected visual acuity (VA) at near 40cm.
timeFrame: 3 month post-surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Palo Alto Medical Foundation
state: California
Study officials:
References:
Clinical trial NCT04805801: The Safety of Emicizumab SC Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors
Official title: Observational Study on the Safety of Hemlibra Subcutaneous Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hemophilia A With Inhibitor
Hemophilia A Without Inhibitor
Lead sponsor: JW Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2021-03-18
Enrollment: 17
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1 .Hemophilia A patients with FVIII inhibitors 2. Severe Hemophilia A patients without FVIII inhibitors

Brief summary: To evaluate Safety and efficacy and pharmacokinetics, FVIII Inhibitor titers of Hemlibra subcutaneous injection (SC inj.) in Korean Hemophilia A patients with/without FVIII Inhibitors.

Detailed description: Target subject :

1. Patients with Hemophilia A with FVIII inhibitors
2. Patients with severe Hemophilia A without FVIII inhibitors.

Eligibility criteria: Inclusion Criteria:

1. Patients with Hemophilia A (congenital factor VIII deficiency) who will receive Hemlibra SC inj. according to medical decision by investigator
2. Signed informed consent form

Exclusion Criteria:

1. Subjects who are hypersensitive to Emicizumab
2. Subjects who are hypersensitive to mouse or hamster protein
3. Subjects with myocardial infarction or the history who are prohibited from administering L-Arginine containing drug
4. Subjects who participated in other clinical trials within a month before enrollment (or the first administration of Hemlibra SC inj.) (Unable to participate in other clinical trials related to Hemophilia A treatment even after enrollment)
5. Subjects who the investigator deems inappropriate for the study.
6. Moderate/Mild for Hemophilia A patients without FVIII inhibitors

Primary outcomes:
measure: Adverse events
timeFrame: for 24weeks
Secondary outcomes:
measure: Annualized Bleeding episode Rate (ABR)
timeFrame: for 24weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Yonsei University Severance Hospital
Study officials:
affiliation: Severance Hospital
name: Chuhl Joo Lyu, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00143104: To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
Official title: A Phase 2, Exploratory Study to Examine the Effects of Inhaled Insulin, Compared With Subcutaneously Administered Insulin, on Airway Lining Fluid Composition in Subjects With Type 1 Diabetes Mellitus.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Diabetes Mellitus, Type 1
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
Collaborators: name: Sanofi
First posted: 2005-09-02
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To examine the lung when people with diabetes take an inhaled form of insulin, compared to subcutaneous insulin.


Eligibility criteria: Inclusion Criteria:

* Type 1 Diabetes Mellitus
* Normal lung function

Exclusion Criteria:

* Smokers

Primary outcomes:
measure: To assess in patients with type 1 diabetes mellitus the effects, if any, on lung lining, fluid cell count and differential within subjects after 12 weeks of inhaled insulin therapy compared to 12 weeks of subcutaneous short-acting therapy.
Secondary outcomes:
measure: (1) Albumin and fibrinogen concentrations, and airway appearance in the above subjects. (2) routine safety, tolerance, and efficacy in the above subjects.
Other outcomes:
Locations:
city: Glendale
country: United States
facility: Pfizer Investigational Site
state: Arizona
city: Fresno
country: United States
facility: Pfizer Investigational Site
state: California
city: San Antonio
country: United States
facility: Pfizer Investigational Site
state: Texas
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT06038604: Glioblastoma Psychosocial Support Program
Official title: Psychosocial Support Program for Patients With Glioblastoma and Their Family Caregivers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glioblastoma
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: Glioblastoma Foundation
First posted: 2023-09-15
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The goal of the study is to conduct a pilot test of the psychosocial support intervention with family caregivers and/or patients coping with glioblastoma.

Detailed description: The specific aims of this study is to pilot test the psychosocial support program for patients with glioblastoma and/or their family caregivers. The investigators will recruit patient-caregiver dyads for the psychosocial support intervention; participants will have the choice whether to take part in the intervention as a dyad or individually given the variability of symptoms and progression of glioblastoma. The investigators will examine acceptability and feasibility of the intervention and examine whether participation in the program can help reduce distress and improve quality of life.

Eligibility criteria: For patients:

Inclusion Criteria:

* Patients who self-report a diagnosis of glioblastoma
* Age \>18 years
* English Speaking

Exclusion Criteria:

* Lacks capacity for interview or is unable to provide informed consent
* Visual or hearing impairments or severe behavioral problems that preclude participation
* Too sick to participate

For caregivers:

Inclusion Criteria:

* Age \>18 years
* English Speaking

Exclusion Criteria:

* Lacks capacity for interview or is unable to provide informed consent
* Visual or hearing impairments or severe behavioral problems that preclude participation
* Too sick to participate

Primary outcomes:
measure: Number of participants who complete study participation
timeFrame: End of study (4-months)
measure: Number of participants who complete post-intervention assessment
timeFrame: End of study (4-months)
measure: Participants' satisfaction with treatment
timeFrame: End of study (4-months)
Secondary outcomes:
measure: Anxiety and depressive symptoms as measured by the Hospital Anxiety and Depression Scale (HADS)
timeFrame: Baseline; Post-intervention follow up (up to 4 months)
measure: General distress as measured by the Distress Thermometer
timeFrame: Baseline; Post-intervention follow up (up to 4 months)
measure: Functional well-being as measured by the Functional Assessment of Cancer Therapy - General (FACT-G)
timeFrame: Baseline; Post-intervention follow up (up to 4 months)
measure: Caregiving efficacy as measured by the caregiver inventory
timeFrame: Baseline; Post-intervention follow up (up to 4 months)
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
Study officials:
affiliation: Duke University
name: Laura S. Porter, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03681704: the Integrated Traditional Chinese and Western Medicine Treat Early Stage DKD
Official title: Multicenter Clinical Study on the Treatment of Early Stage Diabetic Kidney Disease With Integrated Traditional Chinese and Western Medicine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Diabetic Nephropathy Type 2
Keywords: Diabetic Kidney Disease，Traditional Chinese medicine
Lead sponsor: Shanghai University of Traditional Chinese Medicine
Sponsor class: OTHER
Collaborators: name: Shanghai Jiao Tong University Affiliated Sixth People's Hospital
First posted: 2018-09-24
Enrollment: 96
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Efficacy and Safety of treatment with Traditional Chinese Medicine HuangQi Decoctions in Patients with early stage of Diabetic Kidney Disease.

Detailed description: The study is a multi-center, randomized, double-blind, placebo-controlled trial. It is performed in Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, and Shanghai Baoshan District Hospital of Integrated Traditional Chinese Medicine and Western Medicine, China.

Eligibility criteria: Inclusion Criteria:

1. Identify the diagnosis of type 2 diabetes;
2. It meets the medical history of diabetic kidney disease, according to the Mogensen diagnostic staging standard DKD III;
3. Age 18-75 years old, gender ＆ethnicity are not limited;
4. glycated hemoglobin ≤ 10%;
5. Blood pressure is controlled below 130/80mmHg

Exclusion Criteria:

1. Combine other ACEI and ARB application indications other than hypertension;
2. Combine severe primary diseases related to heart, brain, liver and hematopoietic system;
3. Patients who have acute metabolic disorders such as diabetic ketoacidosis occur in the past month;
4. Patients who HBV serological indicators except HbsAb are positive and persistent liver function test transaminase abnormalities;
5. Patients with malignant tumors or history of malignant tumors, history of HIV infection, history of psychosis, acute central nervous system diseases, severe gastrointestinal diseases, and banned use of immunosuppressive agents;
6. Patients with acute renal failure, combined with urinary tract infection, menstrual period, intense exercise, cold and other stress states;
7. pregnant or lactating women;
8. Patients who accepted other clinical trial studies on going ;
9. Patients who combined with serious diseases and dysfunctions in other organs.

Primary outcomes:
measure: ACR
timeFrame: 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Longhua Hospital, Shanghai University of Traditional Chinese Medicine
state: Shanghai
Study officials:
affiliation: Shanghai University of Traditional Chinese Medicine
name: Yueyi Deng, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01907204: Evaluation of Inhaled Treatment in Sinusitis
Official title: Evaluation of Inhaled Corticosteroid Treatment in Sinusitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Sinusitis
Lead sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sponsor class: OTHER
First posted: 2013-07-24
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether inhaled corticosteroid (specially nebulized) could be a good alternative to oral corticosteroid and whether they are effective in the treatment of sinusitis


Eligibility criteria: Inclusion Criteria:

* Nasal/Sinus polyps

Exclusion Criteria:

* Previous sinus surgery
* Age under 18y
* Use of antibiotics

Primary outcomes:
measure: Sniffin' Sticks Test
timeFrame: Baseline and day 15
Secondary outcomes:
measure: Specific quality of life questionnaire (Snot 20)
timeFrame: Baseline and day 15
measure: Retro Olfaction Test
timeFrame: Baseline and day 15
Other outcomes:
Locations:
Study officials:
affiliation: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
name: Gregory Reychler, PhD
role: STUDY_DIRECTOR
affiliation: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
name: Philippe Rombaux, Prof PhD
role: STUDY_DIRECTOR
affiliation: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
name: Coralie Colbrant, PT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01679704: Determination of Glycemic Index (GI) of Ten Food Products
Official title: Determination of Glycemic Index (GI) of Ten Food Products
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glycemic Index
Lead sponsor: Danone Asia Pacific Holdings Pte, Ltd.
Sponsor class: INDUSTRY
First posted: 2012-09-06
Enrollment: 15
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: This study is initiated to investigate the glycemic index value of ten food products.


Eligibility criteria: Inclusion Criteria:

* Healthy non-pregnant females (at least 6 weeks postpartum, non-lactating)
* Age between 21 to 60 years

Exclusion Criteria:

* Suffering from any chronic diseases.
* Suffering from gastrointestinal diseases that may interfere with nutrient absorption, distribution, metabolism and excretion.
* History of diabtes mellitus or use of antihyperglycemic drugs or insulin to treat diabetes and related conditions.
* History of AIDS, hepatitis, renal or heart disease or any other serious complications that may interfere with glucose metabolism.
* Current use of medication that may interfere with the digestion and nutrient absorption (for examples steriods, protease inhibitors or antipsychotics medications).
* Current use of medication known to affect glucose tolerance (excluding oral contraceptives).
* Known food allergy or intolerance.

Primary outcomes:
measure: Glycemic index values of all ten products
timeFrame: 120 minutes post adminstration
Secondary outcomes:
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Temasek Polytechnic
Study officials:
affiliation: Temasek Polytechnic
name: Kalpana Bhaskaran, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00475904: A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)
Official title: A Phase II, Double-Blind, Randomized, Placebo-Controlled Non-inferiority Trial of EpiCept™ NP-1 Topical Cream (2% Ketamine / 4% Amitriptyline) vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Post Herpetic Neuralgia
PHN
Neuropathy
Nerve Pain
Keywords: Post Herpetic Neuralgia
PHN
Neuropathy
Nerve Pain
Topical
Lead sponsor: EpiCept Corporation
Sponsor class: INDUSTRY
First posted: 2007-05-21
Enrollment: 360
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare EpiCept™ NP-1 Topical Cream (2% ketamine / 4% amitriptyline) vs. Oral Gabapentin in the treatment of Postherpetic Neuralgia (PHN)

Detailed description: This is a phase II, multicenter, double-blind, randomized, placebo-controlled, parallel group study of NP-1 and oral gabapentin in approximately 500 patients with PHN. Adult patients with pain resulting from PHN and meeting all other eligibility requirements will be screened for 7 days to determine their average daily pain intensity. Qualifying patients will be randomized on a 2:2:1 basis to NP-1, oral gabapentin, or placebo. The treatment period will be 4-Weeks.

Eligibility criteria: Inclusion Criteria:

* Adult patients with pain for ≥ 3 months following onset of a herpes zoster rash

Exclusion Criteria:

* Clinically significant intercurrent illness (e.g., endocrine, cardiac, hepatic, renal, neurologic, hematologic, skeletal) that the investigator determines could interfere with the efficacy or safety assessments.

Primary outcomes:
measure: Change in Pain Scores Comparing NP-1 Cream vs. Placebo Cream for Treatment of the Pain of Post Herpetic Neuralgia(PHN)From Baseline to 28 Days.
timeFrame: baseline and 28 days
measure: Change in Pain Intensity From Baseline to 28 Days of Treatment, Comparison Between NP-1 Topical Cream and Oral Gabapentin
timeFrame: baseline to 28 Days
Secondary outcomes:
Other outcomes:
Locations:
city: New Delhi
country: India
facility: Multiple Centers
Study officials:
affiliation: University of Rochester
name: Robert H Dworkin, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03930004: Preclinical Cardiomyopathy and Autonomic Function in Type 1 Diabetes
Official title: Preclinical Cardiomyopathy in Type 1 Diabetes: Correlation With Autonomic Dysfunction
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus, Type 1
Diabetic Cardiomyopathies
Autonomic Neuropathy, Diabetic
Lead sponsor: Instituto de Cardiologia de Santa Catarina
Sponsor class: OTHER
First posted: 2019-04-29
Enrollment: 80
Sex: ALL
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Selection of patients from a tertiary hospital.

Brief summary: Type 1 diabetes mellitus is a chronic autoimmune disease, associated with an increased risk of cardiovascular diseases. The development of cardiomyopathy in type 1 diabetes, independent of hypertension and coronary heart disease, is still controversial. A possible mechanism for diabetic cardiomyopathy is autonomic dysfunction. This study aims to evaluate cardiac function and structure, and to relate them with autonomic dysfunction in type 1 diabetes.


Eligibility criteria: Inclusion Criteria:

* type 1 diabetes mellitus

Exclusion Criteria:

* hypertension
* coronary artery disease
* heart valve disease
* ventricular dysfunction
* radiotherapy or chemotherapy
* alcoholism
* limited acoustic window

Primary outcomes:
measure: Preclinical myocardial dysfunction
timeFrame: At patient inclusion.
measure: Left ventricular diastolic dysfunction
timeFrame: At patient inclusion.
measure: Left ventricular hypertrophy
timeFrame: At patient inclusion.
measure: Left atrial dysfunction
timeFrame: At patient inclusion.
Secondary outcomes:
Other outcomes:
Locations:
city: Florianopolis
country: Brazil
facility: HU/UFSC
state: SC
Study officials:
affiliation: HU/UFSC
name: Thais R Weber, MD
role: STUDY_CHAIR
References:
Clinical trial NCT05742204: Plasma Proteomic Biomarkers for Early Diagnosis of Lung Cancer
Official title: Identification and Functional Verification Study in Plasma Proteomic Biomarkers for Early Diagnosis of Lung Cancer
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Lung Cancer
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2023-02-23
Enrollment: 3700
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Study group: Patients with suspected or confirmed diagnosis of lung cancer. Control group: Non-cancer subjects including healthy volunteers, chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.

Brief summary: We will identify plasma proteomics biomarkers for early diagnosis of lung cancer.

Detailed description: We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients and controls. Artificial intelligent (AI) assisted proteomics classifier will be developed for early diagnosis of lung cancer.

Eligibility criteria: Inclusion Criteria:

* CT screening results showed that the size of pulmonary nodules was more than 5mm
* No treatment related to pulmonary nodules/lung cancer (including surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy, etc.)
* Complete clinical and imaging data
* Chest CT/ low-dose spiral CT reports can be provided in the last 3 months
* Voluntarily sign informed consent

Exclusion Criteria:

* There is a history of tumor
* Clinically uncontrolled active infections, such as acute pneumonia, tuberculosis, etc.
* Received any treatment related to pulmonary nodules, such as antibiotics and hormones, in the past 4 weeks
* Complicated with other tumors and serious diseases of the heart, liver, kidney, brain, blood and other systems
* Participated in other clinical trials within the last 3 months
* Combined with liver and kidney insufficiency, hypoproteinemia and other diseases affecting protein content
* You are pregnant or breastfeeding

Primary outcomes:
measure: Plasma proteomic biomarkers
timeFrame: 1 month after surgery
measure: Model or classifier performance
timeFrame: 1 month after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: 2nd Affiliated Hospital, School of Medicine, Zhejiang University
Study officials:
affiliation: 2nd Affiliated Hospital, School of Medicine, Zhejiang University
name: Weilin Wang
role: STUDY_CHAIR
References: